These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 35276407)

  • 21. Macrolides for the treatment of severe respiratory illness caused by novel H1N1 swine influenza viral strains.
    Bermejo-Martin JF; Kelvin DJ; Eiros JM; Castrodeza J; Ortiz de Lejarazu R
    J Infect Dev Ctries; 2009 Apr; 3(3):159-61. PubMed ID: 19759469
    [No Abstract]   [Full Text] [Related]  

  • 22. Levofloxacin and macrolides for treatment of Legionnaires disease: multiple comparisons give few answers.
    Kraus CN; Zalkikar J; Powers JH
    Clin Infect Dis; 2005 Aug; 41(3):416; author reply 416-7. PubMed ID: 16007549
    [No Abstract]   [Full Text] [Related]  

  • 23. Macrolides or fluoroquinolones as enteral antibiotic therapy for non-ICU legionellosis.
    Scussel R; Risso K; Demonchy E; Michelangeli C; Roger PM
    Infection; 2019 Oct; 47(5):875-876. PubMed ID: 31292924
    [No Abstract]   [Full Text] [Related]  

  • 24. Pneumonia: macrolides or amoxicillin for community acquired pneumonia?
    Marchetti F; Berti I
    BMJ; 2006 May; 332(7551):1213-4. PubMed ID: 16710005
    [No Abstract]   [Full Text] [Related]  

  • 25. Septic shock from community-onset pneumonia: is there a role for aspirin plus macrolides combination?
    Falcone M; Russo A; Farcomeni A; Pieralli F; Vannucchi V; Vullo V; Violi F; Venditti M
    Intensive Care Med; 2016 Feb; 42(2):301-2. PubMed ID: 26585791
    [No Abstract]   [Full Text] [Related]  

  • 26. Pharmaceutical Benefits Scheme limitations on macrolides: implications for pertussis management.
    Jarvinen KA; McCall BJ; Nourse CB; McCormack JG; Tilse MH
    Med J Aust; 2006 Mar; 184(6):309. PubMed ID: 16548844
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of macrolides on peripheral arterial disease depends on patient selection and adequate treatment.
    Krayenbuehl PA; Wiesli P; Meier T; Schulthess G
    Eur J Vasc Endovasc Surg; 2005 Sep; 30(3):334-5; author reply 335-7. PubMed ID: 15967691
    [No Abstract]   [Full Text] [Related]  

  • 28. Are newer macrolides effective in eradicating carriage of pertussis?
    Srinivasan R; Yeo TH
    Arch Dis Child; 2005 Mar; 90(3):322-4. PubMed ID: 15723933
    [No Abstract]   [Full Text] [Related]  

  • 29. Antibiotics for asthma?
    Parnham MJ; Oreskovic K
    Pediatr Pulmonol Suppl; 2004; 26():52. PubMed ID: 15029594
    [No Abstract]   [Full Text] [Related]  

  • 30. [Antipseudomonic effect of macrolides. Experience in a case of nosocomial pneumonia caused by multidrug-resistant Pseudomonas aeruginosa without response to antibiotic therapy].
    Barbero JM; Arranz A; Rebollar A; Culebras A; García M; Agudo R; Pérez L; Montero E
    Rev Esp Quimioter; 2018 Feb; 31(1):72-74. PubMed ID: 29390604
    [No Abstract]   [Full Text] [Related]  

  • 31. [The application of macrolide antibiotics in asthma].
    Li XY; She J; Zhu L
    Zhonghua Jie He He Hu Xi Za Zhi; 2019 Jan; 42(1):33-36. PubMed ID: 30630247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BTS guideline for the use of long-term macrolides.
    Congleton J
    Drug Ther Bull; 2021 May; 59(5):67-68. PubMed ID: 33753351
    [No Abstract]   [Full Text] [Related]  

  • 33. Macrolides and community-acquired pneumonia: is quorum sensing the key?
    Wise MP; Williams DW; Lewis MA; Frost PJ
    Crit Care; 2010; 14(4):181. PubMed ID: 20663182
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical implications of the immunomodulatory effects of macrolides on sinusitis.
    Majima Y
    Am J Med; 2004 Nov; 117 Suppl 9A():20S-25S. PubMed ID: 15586560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A randomized controlled study of treating chronic rhinosinusitis with macrolides].
    Li Y; Wu T
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2014 Sep; 28(17):1289-91. PubMed ID: 25522560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunomodulatory effects of macrolides: implications for practicing clinicians.
    Siddiqui J
    Am J Med; 2004 Nov; 117 Suppl 9A():26S-29S. PubMed ID: 15586561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selection of Pneumococci.
    Shah PM
    Dtsch Arztebl Int; 2009 Jan; 106(4):57; author reply 57-8. PubMed ID: 19564975
    [No Abstract]   [Full Text] [Related]  

  • 38. [Application possibility of the macrolides for the RS virus infections].
    Yokota S; Tsutsumi H; Himi T
    Jpn J Antibiot; 2014 Jun; 67(3):147-55. PubMed ID: 25163248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease.
    Smith D; Du Rand I; Addy CL; Collyns T; Hart SP; Mitchelmore PJ; Rahman NM; Saggu R
    Thorax; 2020 May; 75(5):370-404. PubMed ID: 32303621
    [No Abstract]   [Full Text] [Related]  

  • 40. [Bacterial internalization and intracellular activity of quinolones and macrolides].
    Bellussi L; De Benedetto M; Lauriello M; Passali GC; Passali D
    Acta Otorhinolaryngol Ital; 2007 Apr; 27(2 Suppl 87):1-11. PubMed ID: 17702375
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.